Whole Genome MBD-seq reveals different CpG methylation patterns in Azacytidine-treated Juvenile Myelomonocytic Leukaemia (JMML) patients

Br J Haematol. 2018 Sep;182(6):909-912. doi: 10.1111/bjh.14876. Epub 2017 Aug 2.

Affiliations

¹ Department of Paediatric Haematology and Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) "Bambino Gesù" Children's Hospital, Rome, Italy.
² Department of Paediatrics and Adolescent Medicine, Division of Paediatric Haematology and Oncology Medical Centre, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
³ Department of Paediatrics, University of Pavia, Pavia, Italy.

PMID: 28771681
DOI: 10.1111/bjh.14876

No abstract available

Keywords: CpG islands; DNA-methylation; JMML; MBD-seq; azacytidine.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antigens, CD34 / blood
Azacitidine / adverse effects*
Azacitidine / therapeutic use
Binding Sites
Child
Child, Preschool
CpG Islands
DNA Methylation / drug effects*
Epigenesis, Genetic / drug effects
Female
Humans
Leukemia, Myelomonocytic, Juvenile / drug therapy
Leukemia, Myelomonocytic, Juvenile / genetics
Leukemia, Myelomonocytic, Juvenile / therapy*
Male
Sequence Analysis, DNA

Substances

Antigens, CD34
Azacitidine